Lu Kang Pharmaceutical released its 2026 interim report. Total operating revenue was 3.238 billion yuan, up 2.66% year-on-year. Net profit attributable to the parent company was 138 million yuan, up 29.31% year-on-year. Net cash inflow from operating activities was 359 million yuan, up 14.88% year-on-year, marking a second consecutive year of growth. The company's asset-liability ratio was 45.18%, down 8.78 percentage points from the same period last year. Gross margin was 22.18%, up 0.86 percentage points from the previous quarter. Diluted earnings per share were 0.13 yuan, up 8.33% year-on-year.
Shandong Lukang Pharmaceutical Co LtdNet profit up 29.31% year-on-year, revenue up 2.66%, and improved margins and lower debt.